Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome : = Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome

Comparison of two groups of patients SARS-CoV-2 positive with severe acute respiratory syndrome: 1. Exposed to low prolonged doses of Methylprednisolone 2. Not exposed to corticosteroids (standard of care alone) The two group will be weighted by means of a propensity score according to: 1. Sex 2. Age 3. C-reactive protein (CRP) at baseline 4. Sequential Organ Failure Assessment (SOFA) score at baseline 5. PaO2/FiO2 ratio at baseline (ratio of arterial oxygen partial pressure to fractional inspired oxygen) Anti-viral agents, chloroquine, respiratory support (any), and antibiotics (any) are allowed in each study group. Corticosteroids use, other than per-protocol Methylprednisolone in the exposed group is a reason for dropout. 1. The exposed group is treated with Methylprednisolone at study entry (baseline) according to a protocol based on the Italian national recommendations for COVID-19 management: a loading dose of 80 mg/kg IV, followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to < 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient. 2. Unexposed patients will be selected from concurrent consecutive COVID-19 patients with the same inclusion and exclusion criteria and blinded to outcome data.

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, June 4, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: ARDS, Human
Clinical Study Status: Completed
Clinical Study
Coronavirus Infections
Coronavirus Infections > MeSH
Forschungsbericht
Klinische Studie
Pneumonia > MeSH
Respiratory Distress Syndrome, Adult > MeSH
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Severe Acute Respiratory Syndrome > MeSH
Syndrome > MeSH
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: June 4, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04323592

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03836nam a22005532 4500
001 CTG003342565
003 DE-627
005 20200609024404.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG003342565 
035 |a (DE-599)NCTNCT04323592 
035 |a (NCT)MP-19 023_2020 
035 |a (NCT)NCT04323592 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome  |b  = Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome 
246 3 1 |a Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c June 4, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: June 4, 2020 
500 |a Last updated: 2020-06-08 
520 |a Comparison of two groups of patients SARS-CoV-2 positive with severe acute respiratory syndrome: 1. Exposed to low prolonged doses of Methylprednisolone 2. Not exposed to corticosteroids (standard of care alone) The two group will be weighted by means of a propensity score according to: 1. Sex 2. Age 3. C-reactive protein (CRP) at baseline 4. Sequential Organ Failure Assessment (SOFA) score at baseline 5. PaO2/FiO2 ratio at baseline (ratio of arterial oxygen partial pressure to fractional inspired oxygen) Anti-viral agents, chloroquine, respiratory support (any), and antibiotics (any) are allowed in each study group. Corticosteroids use, other than per-protocol Methylprednisolone in the exposed group is a reason for dropout. 1. The exposed group is treated with Methylprednisolone at study entry (baseline) according to a protocol based on the Italian national recommendations for COVID-19 management: a loading dose of 80 mg/kg IV, followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to < 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient. 2. Unexposed patients will be selected from concurrent consecutive COVID-19 patients with the same inclusion and exclusion criteria and blinded to outcome data. 
650 4 |a Clinical Study Status: Completed 
650 4 |a Severe Acute Respiratory Syndrome (SARS) Pneumonia 
650 4 |a Coronavirus Infections 
650 4 |a ARDS, Human 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
650 4 |a Coronavirus Infections  |x MeSH 
650 4 |a Severe Acute Respiratory Syndrome  |x MeSH 
650 4 |a Pneumonia  |x MeSH 
650 4 |a Respiratory Distress Syndrome, Adult  |x MeSH 
650 4 |a Syndrome  |x MeSH 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a University of Trieste  |e Herausgebendes Organ  |4 isb 
787 0 8 |a Nicastri E, Petrosillo N, Bartoli TA, Lepore L, Mondi A, Palmieri F, D'Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A  |t National Institute for the Infectious Diseases "L  |w (NLM)32218915 
856 4 0 |u https://clinicaltrials.gov/show/NCT04323592  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 4  |c 06 
951 |a BO 
952 |j 2020  |b 4  |c 06